Headlines about Immune Design (NASDAQ:IMDZ) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Design earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.6488553365256 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Risky factor of Immune Design Corp. (IMDZ) is observed at 2.10 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- $810,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter (americanbankingnews.com)
- Immune Design (IMDZ) Upgraded by Zacks Investment Research to “Buy” (americanbankingnews.com)
- Ambitious techies roll out robots, smart gear for their elders (record-bee.com)
- Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development (bizjournals.com)
IMDZ has been the topic of several research analyst reports. Cowen restated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research note on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $13.13.
In other Immune Design news, major shareholder Leo Guthart purchased 20,000 shares of Immune Design stock in a transaction dated Monday, January 8th. The stock was purchased at an average price of $3.90 per share, with a total value of $78,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Carlos V. Paya sold 7,970 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.17, for a total transaction of $33,234.90. Following the sale, the chief executive officer now directly owns 114,560 shares of the company’s stock, valued at approximately $477,715.20. The disclosure for this sale can be found here. Insiders have sold a total of 13,959 shares of company stock valued at $58,209 in the last ninety days. Insiders own 20.70% of the company’s stock.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.